Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

…, EF Smit, C Faivre-Finn, TS Mok, M Reck… - Annals of …, 2018 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer,
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …

First-line immunotherapy for non–small-cell lung cancer

M Reck, J Remon, MD Hellmann - Journal of Clinical Oncology, 2022 - ingentaconnect.com
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has been
characterized by critical progress that has contributed to substantially improved survival. In …

Management of non-small-cell lung cancer: recent developments

M Reck, DF Heigener, T Mok, JC Soria, KF Rabe - The Lancet, 2013 - thelancet.com
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we …

[HTML][HTML] Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer

M Reck, D Rodríguez-Abreu… - … England Journal of …, 2016 - Mass Medical Soc
Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …

[HTML][HTML] Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer

…, JG Aerts, M Domine, L Paz-Ares, M Reck… - … England Journal of …, 2015 - Mass Medical Soc
Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC)
who have disease progression during or after first-line chemotherapy have limited treatment …

[HTML][HTML] Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

…, M Reck, R Hui, EB Garon, M Boyer… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

[HTML][HTML] Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC

…, A Lopez-Chavez, A Sandler, M Reck - … England Journal of …, 2018 - Mass Medical Soc
Background The cancer-cell–killing property of atezolizumab may be enhanced by the blockade
of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. …

[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

…, ML Johnson, M Nishio, M Reck… - … England Journal of …, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …

[HTML][HTML] First-line nivolumab in stage IV or recurrent non–small-cell lung cancer

DP Carbone, M Reck, L Paz-Ares… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …

[HTML][HTML] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC

…, C Faivre-Finn, M Reck… - … England Journal of …, 2018 - Mass Medical Soc
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …